Open AccessA Randomized Treatment Trial: Single Versus 7-Day Dose of Metronidazole for The Treatment of Trichomonas Vaginalis Among HIV-Infected Women
Author(s) -
Patricia Kissinger,
Leandro Mena,
Judy Levison,
Rebecca A. Clark,
Megan Gatski,
Harold Henderson,
Norine Schmidt,
Susan L. Rosenthal,
Leann Myers,
David H. Martín
Publication year - 2010
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3181eda955
Subject(s) - medicine , trichomonas vaginalis , confidence interval , metronidazole , randomized controlled trial , relative risk , trichomoniasis , trichomonas vaginitis , gynecology , obstetrics , antibiotics , biology , microbiology and biotechnology
To determine if the metronidazole (MTZ) 2-gm single dose (recommended) is as effective as the 7-day 500 mg twice a day dose (alternative) for treatment of Trichomonas vaginalis (TV) among HIV+ women.